Log in
NASDAQ:ADAP

Adaptimmune Therapeutics Stock Forecast, Price & News

$10.43
-0.32 (-2.98 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.18
Now: $10.43
$10.83
50-Day Range
$7.82
MA: $8.50
$10.78
52-Week Range
$0.71
Now: $10.43
$13.40
Volume535,998 shs
Average Volume2.00 million shs
Market Capitalization$1.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.08
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Read More
Adaptimmune Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADAP
CUSIPN/A
Phone44-12-3543-0000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 million
Book Value$1.18 per share

Profitability

Net Income$-137,160,000.00
Net Margins-5,687.30%

Miscellaneous

Employees406
Market Cap$1.36 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$10.43
-0.32 (-2.98 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADAP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions

How has Adaptimmune Therapeutics' stock been impacted by Coronavirus?

Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADAP stock has increased by 254.8% and is now trading at $10.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Adaptimmune Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Adaptimmune Therapeutics
.

When is Adaptimmune Therapeutics' next earnings date?

Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Adaptimmune Therapeutics
.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) posted its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, meeting the consensus estimate of ($0.24). The biotechnology company earned $0.50 million during the quarter, compared to the consensus estimate of $0.95 million. Adaptimmune Therapeutics had a negative return on equity of 58.60% and a negative net margin of 5,687.30%.
View Adaptimmune Therapeutics' earnings history
.

What price target have analysts set for ADAP?

6 analysts have issued 1-year price objectives for Adaptimmune Therapeutics' stock. Their forecasts range from $5.00 to $42.00. On average, they expect Adaptimmune Therapeutics' stock price to reach $16.50 in the next year. This suggests a possible upside of 58.2% from the stock's current price.
View analysts' price targets for Adaptimmune Therapeutics
.

Are investors shorting Adaptimmune Therapeutics?

Adaptimmune Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 3,250,000 shares, a decline of 18.8% from the August 15th total of 4,000,000 shares. Based on an average trading volume of 799,600 shares, the days-to-cover ratio is currently 4.1 days.
View Adaptimmune Therapeutics' Short Interest
.

Who are some of Adaptimmune Therapeutics' key competitors?

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

Who are Adaptimmune Therapeutics' key executives?

Adaptimmune Therapeutics' management team includes the following people:
  • Mr. James Julian Noble, CEO & Director (Age 60)
  • Dr. Helen Katrina Tayton-Martin, Co-Founder & Chief Bus. Officer (Age 52)
  • Mr. Adrian Rawcliffe, Chief Financial Officer (Age 47)
  • Mr. William C. Bertrand Jr., Chief Operating Officer (Age 54)
  • Dr. Rafael Amado, Pres of R&D (Age 55)

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (2.00%), FMR LLC (1.94%), FMR LLC (1.94%), Victory Capital Management Inc. (1.47%), Avidity Partners Management LP (1.11%) and Rathbone Brothers plc (0.34%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Elliot Norry, Gavin Wood, Gwendolyn Knowlt Binder-Scholl, James Noble, John Lunger, Lawrence M Alleva, Peter W Sonsini, Rafael Amado and William C Bertrand, Jr.
View institutional ownership trends for Adaptimmune Therapeutics
.

Which institutional investors are selling Adaptimmune Therapeutics stock?

ADAP stock was sold by a variety of institutional investors in the last quarter, including WS Management Lllp. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Elliot Norry, James Noble, John Lunger, and William C Bertrand, Jr.
View insider buying and selling activity for Adaptimmune Therapeutics
.

Which institutional investors are buying Adaptimmune Therapeutics stock?

ADAP stock was purchased by a variety of institutional investors in the last quarter, including RTW Investments LP, Victory Capital Management Inc., Avidity Partners Management LP, FMR LLC, FMR LLC, Goldman Sachs Group Inc., Marshall Wace North America L.P., and Perceptive Advisors LLC. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Gavin Wood, Lawrence M Alleva, and Peter W Sonsini.
View insider buying and selling activity for Adaptimmune Therapeutics
.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $10.43.

How big of a company is Adaptimmune Therapeutics?

Adaptimmune Therapeutics has a market capitalization of $1.36 billion and generates $1.12 million in revenue each year. The biotechnology company earns $-137,160,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.

What is Adaptimmune Therapeutics' official website?

The official website for Adaptimmune Therapeutics is www.adaptimmune.com.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.